Microsatellite Stable Colorectal Carcinoma Clinical Trials

2 recruiting

Microsatellite Stable Colorectal Carcinoma Trials at a Glance

5 actively recruiting trials for microsatellite stable colorectal carcinoma are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Irvine, Pittsburgh, and Orange. Lead sponsors running microsatellite stable colorectal carcinoma studies include National Cancer Institute (NCI), Dan Feng, and Fudan University.

Browse microsatellite stable colorectal carcinoma trials by phase

Treatments under study

About Microsatellite Stable Colorectal Carcinoma Clinical Trials

Looking for clinical trials for Microsatellite Stable Colorectal Carcinoma? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Microsatellite Stable Colorectal Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Microsatellite Stable Colorectal Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 15 of 5 trials

Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

Stage IV Colorectal Cancer AJCC v8Metastatic Microsatellite Stable Colorectal CarcinomaRefractory Microsatellite Stable Colorectal Carcinoma
National Cancer Institute (NCI)39 enrolled8 locationsNCT06654037
Recruiting
Phase 1Phase 2

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Hematopoietic and Lymphatic System NeoplasmMetastatic Malignant Solid NeoplasmStage IV Colorectal Cancer AJCC v8+4 more
National Cancer Institute (NCI)58 enrolled23 locationsNCT05691491
Recruiting
Phase 1Phase 2

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

Metastatic Microsatellite Stable Colorectal Carcinoma
Dan Feng24 enrolled1 locationNCT07281716
Recruiting
Phase 2

Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

Colorectal Cancer MetastaticMicrosatellite Stable Colorectal CarcinomaRefractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS36 enrolled2 locationsNCT06522919
Recruiting
Phase 2

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Metastatic Colorectal CancerRAS MutationCadonilimab+1 more
Fudan University53 enrolled1 locationNCT06218810